Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

These Analysts Revise Their Forecasts On Evolent Health After Upbeat Results

Published 23/02/2024, 19:31
© Reuters.  These Analysts Revise Their Forecasts On Evolent Health After Upbeat Results
EVH
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

Evolent Health, Inc. (NYSE: EVH) reported better-than-expected fourth-quarter results on Thursday.

Evolent Health posted quarterly earnings of 23 cents per share, beating market estimates of 15 cents per share. The company’s quarterly sales came in at $556.05 million versus market expectations of $542.39 million, according to data from Benzinga Pro.

Seth Blackley, Chief Executive Officer, and Co-Founder of Evolent stated, "We ended 2023 on a strong note, achieving all of our financial objectives for the year. Annual revenue increased over 45% while we continued to deliver strong earnings, driven by continued underlying growth as well as the successful integration of NIA. I am incredibly proud of our global team who worked so hard to collectively deliver what we promised to both shareholders and partners in 2023. Our financial position is strong as cash flow exceeded our target for the year and we significantly improved our cash and balance sheet flexibility."

Evolent Health shares gained 11.5% to trade at $33.20 on Friday.

These analysts made changes to their price targets on Evolent Health after the company reported results for the recent quarter.

  • Canaccord Genuity cut the price target on Evolent Health from $47 to $45. Canaccord Genuity analyst Richard Close maintained a Buy rating.
  • JMP Securities raised the price target on Evolent Health from $37 to $38. JMP Securities analyst Constantine Davides maintained a Market Outperform rating.

Also Check This Out: Jim Cramer: Unity Software 'Had Problems,' But Zscaler Is A 'Good One' To Buy

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest Ratings for EVH

Nov 2021JP MorganUpgradesNeutralOverweight
Aug 2021Canaccord GenuityMaintainsBuy
Mar 2021Canaccord GenuityMaintainsBuy

View the Latest Analyst Ratings

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.